Unleashing Potential | Dana-Farber Cancer Institute
AI-based cancer diagnostic tools have fit rather seamlessly into clinical practice. They have also hinted at the potential for AI to benefit patients in other ways.
AI-based cancer diagnostic tools have fit rather seamlessly into clinical practice. They have also hinted at the potential for AI to benefit patients in other ways.
Frontline nivolumab plus chemotherapy has been recommended for approval in unresectable or metastatic urothelial carcinoma.
Robert W. Mutter, MD, discusses personalized treatment approaches with radiation and endocrine therapy with
The phase 2 DENALI trial is investigating azenosertib in patients with high-grade serous ovarian cancer.
Kian-Huat Lim, MD, PhD, discusses the current treatment landscape for metastatic pancreatic cancer.
Glecirasib elicited responses and demonstrated a manageable safety profile in patients with pretreated advanced NSCLC harboring KRAS G12C mutations.
R. Lor Randall, MD, FACS, discusses research examining ALDH1A1 and CD44, potential markers of osteosarcoma stem cells, and how further research may be warranted with…
Benjamin Tomlinson, MD, discusses the first-line approval of luspatercept and other ongoing research in low-risk MDS.
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care
Katherine Wang, MD, discusses the role of active surveillance for patients with renal masses and the ongoing MUSIC-KIDNEY project in Michigan.
An abstract is unavailable.